EE05633B1 - Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine - Google Patents
Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamineInfo
- Publication number
- EE05633B1 EE05633B1 EEP200200507A EEP200200507A EE05633B1 EE 05633 B1 EE05633 B1 EE 05633B1 EE P200200507 A EEP200200507 A EE P200200507A EE P200200507 A EEP200200507 A EE P200200507A EE 05633 B1 EE05633 B1 EE 05633B1
- Authority
- EE
- Estonia
- Prior art keywords
- mva
- preparation
- virus ankara
- pharmaceutical composition
- host cell
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/08—Inactivation or attenuation by serial passage of virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000410 | 2000-03-14 | ||
| PCT/EP2001/002703 WO2001068820A1 (en) | 2000-03-14 | 2001-03-10 | Altered strain of the modified vaccinia virus ankara (mva) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200200507A EE200200507A (et) | 2004-02-16 |
| EE05633B1 true EE05633B1 (et) | 2013-02-15 |
Family
ID=8159327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200507A EE05633B1 (et) | 2000-03-14 | 2001-03-10 | Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6682743B2 (https=) |
| EP (1) | EP1263936B1 (https=) |
| JP (1) | JP4759201B2 (https=) |
| KR (1) | KR100880765B1 (https=) |
| CN (1) | CN1291012C (https=) |
| AT (1) | ATE305030T1 (https=) |
| AU (1) | AU780696B2 (https=) |
| BR (1) | BR0109158A (https=) |
| CA (1) | CA2397675C (https=) |
| CZ (1) | CZ293690B6 (https=) |
| DE (1) | DE60113512T2 (https=) |
| DK (1) | DK1263936T3 (https=) |
| EE (1) | EE05633B1 (https=) |
| ES (1) | ES2249430T3 (https=) |
| HK (1) | HK1052725B (https=) |
| HU (1) | HU228691B1 (https=) |
| IL (3) | IL150736A0 (https=) |
| MX (1) | MXPA02008873A (https=) |
| NO (1) | NO20024246D0 (https=) |
| NZ (1) | NZ521270A (https=) |
| PL (1) | PL205922B1 (https=) |
| RU (1) | RU2280075C2 (https=) |
| SI (1) | SI1263936T1 (https=) |
| UA (1) | UA84388C2 (https=) |
| WO (1) | WO2001068820A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| PL212047B1 (pl) | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| EP1357127A1 (de) * | 2002-04-10 | 2003-10-29 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
| NZ536592A (en) | 2002-04-19 | 2007-01-26 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccination of neonates |
| CN102703393A (zh) * | 2002-05-16 | 2012-10-03 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| JP2005537793A (ja) | 2002-09-05 | 2005-12-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法 |
| EP1601333B1 (en) | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
| US7423155B2 (en) | 2003-11-14 | 2008-09-09 | 3M Innovative Properties Company | N-sulfonyldicarboximide containing tethering compounds |
| EP1845164B1 (en) * | 2003-11-24 | 2010-06-16 | Bavarian Nordic A/S | Promoters for expression in modified vaccinia virus ankara |
| DE102004003572A1 (de) * | 2004-01-23 | 2005-08-18 | Bavarian Nordic A/S | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens |
| US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
| EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| US7607323B1 (en) | 2007-10-16 | 2009-10-27 | Hall Charles F | Curl resistant shirt collar and method of fabricating same |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| US9005632B2 (en) | 2009-11-20 | 2015-04-14 | Takeda Vaccines, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains |
| JP5798124B2 (ja) * | 2009-11-20 | 2015-10-21 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | ワクチン構築物におけるポックスウイルスエレメントに関する免疫原性組成物 |
| WO2011087839A1 (en) | 2009-12-22 | 2011-07-21 | Baxter International Inc. | Vaccine to influenza a virus |
| WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| WO2015138471A1 (en) * | 2014-03-10 | 2015-09-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Heat inactivated poxvirus improves vaccination results |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| NL2014148B1 (en) | 2015-01-16 | 2017-01-05 | Univ Erasmus Med Ct Rotterdam | Combination vaccine for camelids. |
| EP4122492A1 (en) * | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| TW202523682A (zh) | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| EP3446119A1 (en) | 2016-04-18 | 2019-02-27 | The Broad Institute Inc. | Improved hla epitope prediction |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| KR102658198B1 (ko) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
| CN110603058A (zh) | 2017-05-15 | 2019-12-20 | 扬森疫苗与预防公司 | 含有病毒的稳定组合物 |
| EP3973973A1 (en) | 2017-10-31 | 2022-03-30 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| CN111315407B (zh) | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
| WO2023215782A2 (en) * | 2022-05-04 | 2023-11-09 | University Of Maryland, College Park | Rna vectors with hairpin-like inserts |
| US20230364227A1 (en) | 2022-05-12 | 2023-11-16 | Pellis Therapeutics, Inc. | Poxvirus adjuvant for t-cell vaccination |
| WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
| US12562256B2 (en) * | 2023-11-07 | 2026-02-24 | New York University | Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| DE4405841C1 (de) | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| RU2076735C1 (ru) * | 1994-03-23 | 1997-04-10 | ГНЦВБ "Вектор" | Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| KR100373480B1 (ko) * | 1997-10-15 | 2003-02-25 | 아사히 가세이 가부시키가이샤 | 트롬보모듈린 수용액 주사제의 저장 및 유통시의 품질유지 방법 |
| JP3736622B2 (ja) * | 2001-06-15 | 2006-01-18 | セイコーエプソン株式会社 | ライン駆動回路、電気光学装置及び表示装置 |
-
2001
- 2001-03-10 CN CNB018064949A patent/CN1291012C/zh not_active Expired - Fee Related
- 2001-03-10 DK DK01931508T patent/DK1263936T3/da active
- 2001-03-10 HK HK03104648.5A patent/HK1052725B/zh not_active IP Right Cessation
- 2001-03-10 HU HU0300120A patent/HU228691B1/hu not_active IP Right Cessation
- 2001-03-10 SI SI200130452T patent/SI1263936T1/sl unknown
- 2001-03-10 RU RU2002124622/13A patent/RU2280075C2/ru not_active IP Right Cessation
- 2001-03-10 UA UA2002097453A patent/UA84388C2/ru unknown
- 2001-03-10 ES ES01931508T patent/ES2249430T3/es not_active Expired - Lifetime
- 2001-03-10 US US10/204,782 patent/US6682743B2/en not_active Expired - Fee Related
- 2001-03-10 CZ CZ20023061A patent/CZ293690B6/cs not_active IP Right Cessation
- 2001-03-10 IL IL15073601A patent/IL150736A0/xx active IP Right Grant
- 2001-03-10 JP JP2001567304A patent/JP4759201B2/ja not_active Expired - Fee Related
- 2001-03-10 MX MXPA02008873A patent/MXPA02008873A/es active IP Right Grant
- 2001-03-10 EE EEP200200507A patent/EE05633B1/xx not_active IP Right Cessation
- 2001-03-10 WO PCT/EP2001/002703 patent/WO2001068820A1/en not_active Ceased
- 2001-03-10 KR KR1020027012058A patent/KR100880765B1/ko not_active Expired - Fee Related
- 2001-03-10 BR BR0109158-1A patent/BR0109158A/pt not_active Application Discontinuation
- 2001-03-10 AT AT01931508T patent/ATE305030T1/de active
- 2001-03-10 CA CA2397675A patent/CA2397675C/en not_active Expired - Fee Related
- 2001-03-10 DE DE60113512T patent/DE60113512T2/de not_active Expired - Lifetime
- 2001-03-10 PL PL357378A patent/PL205922B1/pl not_active IP Right Cessation
- 2001-03-10 EP EP01931508A patent/EP1263936B1/en not_active Expired - Lifetime
- 2001-03-10 NZ NZ521270A patent/NZ521270A/xx not_active IP Right Cessation
- 2001-03-10 AU AU58269/01A patent/AU780696B2/en not_active Ceased
-
2002
- 2002-07-15 IL IL150736A patent/IL150736A/en not_active IP Right Cessation
- 2002-09-05 NO NO20024246A patent/NO20024246D0/no not_active Application Discontinuation
-
2008
- 2008-01-08 IL IL188667A patent/IL188667A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200507A (et) | Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine | |
| WO2000020027A3 (en) | Methods for therapeutic vaccination | |
| EP1203817A3 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
| AU2001295671A1 (en) | Pharmaceutical composition for immunisation against aids | |
| PT1409692E (pt) | Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| MXPA01011047A (es) | Secuencias genomicas de neisseria y metodos para su uso. | |
| WO2000057917A3 (en) | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines | |
| IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
| WO2005007673A3 (en) | Immunogenic peptides | |
| WO2002036790A3 (en) | Influenza virus vector for infection of dendritic cells | |
| NZ337885A (en) | vaccine formulation of an antigen, a TH-1 inducing adjuvant and a sparingly water soluble amino acid | |
| EP1471936A4 (en) | HIV VACCINE AND METHOD OF USE | |
| AU2002310474A1 (en) | Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same | |
| WO2003093298A3 (en) | Immunogenic peptides | |
| WO2000052045A3 (en) | Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof | |
| EP1667634A4 (en) | VACCINE AGAINST ANTHRAX | |
| FR2809960B1 (fr) | Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante | |
| BR9905780A (pt) | Antìgenos vacinais de leptospira para prevenção da laptospirose | |
| NZ514027A (en) | Cloning and expression of haemophilus somnus transferrin-binding proteins | |
| WO2002085409A3 (en) | Methods and compositions for inducing an immune response to an antigen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE1A | Change of address | ||
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20140310 |